QUVIVIQ

QUVIVIQ is a prescription medication developed by Idorsia Pharmaceuticals Ltd, a Swiss biopharmaceutical company. It is used for the treatment of insomnia in adults, characterized by difficulties with sleep onset and/or sleep maintenance. The active ingredient in QUVIVIQ is daridorexant, a dual orexin receptor antagonist that helps regulate the sleep-wake cycle. Manufacturing of QUVIVIQ occurs in multiple countries to meet global demand. As of January 2026, Idorsia Pharmaceuticals Ltd remains the ultimate owner of the QUVIVIQ brand, with no known subsidiaries managing the brand locally.